• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Jornay PM Nighttime Stimulant for Next-Morning Effect

Jornay PM Nighttime Stimulant for Next-Morning Effect

November 1, 2018
Talia Puzantian, PharmD, BCPP
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Talia Puzantian, PharmD, BCPP Dr. Puzantian has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Prescribing bedtime stimulants sounds like a recipe for a bad night’s sleep. But the FDA recently approved Jornay PM, which is an extended release (ER) formulation of methylphenidate that is, in fact, dosed at night.

Approved for kids age 6 and older, Jornay PM has an extremely delayed onset of effect of 10 hours. This means kids can take it at around 8 pm and it won’t actually kick in until about 6 am, so symptom control appears early in the morning. Jornay PM is cleverly formulated. The methylphenidate is delivered using a technology called “Delexis,” a 2-layer drug delivery system that allows no more than 5% of the drug to be absorbed within the first 10 hours. After this initial lag period, controlled release of the drug occurs between 10–24 hours after administration, with peak levels around 14 hours post-dose.

Approval was based on 2 trials. The first was a 6-week study of 43 kids already taking methylphenidate who were switched to Jornay PM (Wigal S et al, 29th Annual US Psychiatric and Mental Health Congress poster 2016). Over 1 week, the Jornay dose was optimized (mean dose 65.6 mg), and then kids were randomized to either continue Jornay or switch to placebo. After 6 weeks, the kids in the Jornay group showed significantly more improvement compared to placebo in both teacher and parent ratings. The second study was a 3-week, randomized, double-blind study in 161 kids with ADHD that also showed significant improvement with Jornay over placebo (Pliszka SR et al, J Child Adolesc Psychopharmacol 2017;27(6):474–482).

Side effects were similar to other methylphenidate formulations, although insomnia was reported in 41% of patients in the open-label phase of the first trial. Moving forward, it will be important to see whether sleep and appetite are problematic vs other medications or placebo. Jornay PM will be available in 20 mg, 40 mg, 60 mg, 80 mg, and 100 mg ER capsules with a dosing range of 20–100 mg QPM. Pricing information is not yet available as the medication won’t hit pharmacy shelves until early 2019.
Child Psychiatry
KEYWORDS adhd news_of_note sleep_disorders
Puzantian 150x150
Talia Puzantian, PharmD, BCPP

Treating Alcohol Use Disorder—A Fact Book (2023)

More from this author
www.thecarlatreport.com
Issue Date: November 1, 2018
SUBSCRIBE NOW
Table Of Contents
Note From the Editor-in-Chief
CME Post-Test - ADHD in Children and Adolescents, CCPR, November/December 2018
Evaluating and Treating Co-Occurring ADHD and Bipolar Disorder
Becoming Successful Despite ADHD
Assessing and Treating Violence in Patients
Is Cannabis Bad for Cognition?
Jornay PM Nighttime Stimulant for Next-Morning Effect
DOWNLOAD NOW
Featured Book
  • CMFB2e_Cover.png

    Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

    All the important facts covering child and adolescent psychopharmacology.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • teen_depression.jpeg
    Child Psychiatry

    Assessment of Non-Suicidal Self-Injury in Children and Adolescents

    Learn how to assess and intervene with NSSI, including ideas for supporting autonomy while addressing the behavior.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.